The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC).
 
Enriqueta Felip
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Roche Pharma AG
 
Sergey Orlov
No Relationships to Disclose
 
Keunchil Park
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AVEO; Boehringer Ingelheim; Clovis Oncology; Hanmi; Kyowa Hakko Kirin; Lilly; Novartis; Ono Pharmaceutical; Roche Pharma AG
Research Funding - AstraZeneca (Inst)
 
Chong-Jen Yu
Consulting or Advisory Role - Roche Pharma AG
 
Chun-Ming Tsai
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; MSD; Pfizer; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly; Pfizer; Roche Pharma AG
Research Funding - AstraZeneca (Inst)
 
Makoto Nishio
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Lilly; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Speakers' Bureau - AstraZeneca; Chugai Pharma; Elekta; Lilly; Nicholas Piramal; Novartis; Pfizer; Sanofi; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst)
 
Manuel Cobo Dols
No Relationships to Disclose
 
Mark James McKeage
Consulting or Advisory Role - Novartis; Pfizer
Research Funding - Novartis (Inst); OncoMed (Inst); Roche Pharma AG (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Wu-Chou Su
No Relationships to Disclose
 
Tony Mok
Employment - The Chinese University of Hong Kong
Honoraria - Amgen; AstraZeneca; AVEO; Biomarin; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Eisai; Janssen; Lilly; Merck Serono; Novartis; Pfizer; Roche/Genentech; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; AstraZeneca; AVEO; Biomarin; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Eisai; Janssen; Lilly; Merck Serono; Novartis; Pfizer; Roche/Genentech; Taiho Pharmaceutical
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Lilly; Merck Serono; Pfizer; Roche
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Boehringer Ingelheim; Lilly; Merck Serono; Pfizer; Roche
 
Giorgio V. Scagliotti
Honoraria - AstraZeneca; Clovis Oncology; Lilly; Pfizer; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Lilly; Roche Pharma AG
Speakers' Bureau - Lilly
 
David Spigel
Consulting or Advisory Role - Novartis
Speakers' Bureau - Novartis
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Novartis
 
Fabrice Branle
Employment - Novartis
 
Chetachi Emeremni
Employment - Novartis
 
Massimiliano Quadrigli
Employment - Novartis; Novartis (I)
 
Alice Tsang Shaw
Honoraria - Novartis; Pfizer; Roche Pharma AG
Consulting or Advisory Role - Genentech; Ignyta; Novartis; Pfizer; Roche Pharma AG
Research Funding - ARIAD (Inst); Genentech (Inst); Novartis (Inst); Pfizer (Inst)